Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.48
-1.7%
$1.34
$0.87
$6.78
$149.99M0.74836,600 shs233,289 shs
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.60
+5.3%
$1.17
$1.78
$40.66
$58.79M1.4620,672 shs311,074 shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.59
+1.0%
$1.83
$0.91
$6.05
$214.30M2.152.61 million shs1.91 million shs
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
$16.70
$16.59
$4.24
$16.72
$380.09M0.55157,287 shsN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$46.99
$46.50
$28.21
$62.00
$3.54B0.682.56 million shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+5.63%+0.67%+8.70%+37.61%-65.44%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-7.88%+4.83%+46.15%+15.15%+109.66%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+13.78%+16.89%+44.63%+128.57%-43.61%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.00%0.00%0.00%0.00%0.00%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00%+0.04%+0.69%+9.10%+26.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alector, Inc. stock logo
ALEC
Alector
3.6477 of 5 stars
3.13.00.04.50.02.50.0
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
4.379 of 5 stars
3.23.00.04.23.22.50.6
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
1.7138 of 5 stars
3.12.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.14
Hold$4.00171.19% Upside
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.31
Hold$4.7081.82% Upside
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.00
N/AN/AN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
2.13
Hold$52.5711.88% Upside

Current Analyst Ratings Breakdown

Latest CRTX, EDIT, SWTX, ALEC, and ORTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.00
5/12/2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.00
5/9/2025
Alector, Inc. stock logo
ALEC
Alector
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
4/30/2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$74.00 ➝ $47.00
4/29/2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
4/29/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/29/2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$66.00 ➝ $47.00
4/28/2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$77.00 ➝ $47.00
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$3.00
4/28/2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$100.56M1.47N/AN/A$1.29 per share1.14
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$32.31M6.70N/AN/A$1.63 per share1.59
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
$22.66M16.77N/AN/A$7.74 per share2.16
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$191.59M18.48N/AN/A$6.47 per share7.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
-$150.66M-$0.94N/AN/AN/A-333.90%-74.94%-33.51%N/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%8/6/2025 (Estimated)

Latest CRTX, EDIT, SWTX, ALEC, and ORTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million
5/9/2025Q1 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
N/AN/AN/AN/AN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.08
3.08
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.20
3.12
2.98
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
4.33
4.18

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
29.90%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
9.10%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
2.91%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
7.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23083.71 million81.96 millionOptionable
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
16622.76 million22.10 millionOptionable
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
23075.35 million69.45 millionOptionable

Recent News About These Companies

Biotech Stocks To Consider - June 16th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alector stock logo

Alector NASDAQ:ALEC

$1.48 -0.03 (-1.67%)
Closing price 03:51 PM Eastern
Extended Trading
$1.48 0.00 (0.00%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.60 +0.08 (+5.26%)
As of 07/2/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$2.58 +0.03 (+0.98%)
Closing price 03:48 PM Eastern
Extended Trading
$2.60 +0.01 (+0.39%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Orchard Therapeutics stock logo

Orchard Therapeutics NASDAQ:ORTX

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

SpringWorks Therapeutics stock logo

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)
As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.